SPEED™ Dry Eye Questionnaire Validated
MORRISVILLE, N.C., — October 17, 2013 — TearScience, Inc., a privately held medical device company, today announced that its Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire has been validated by the Centre for Contact Lens Research at the School of Optometry and Vision Science at the University of Waterloo and published recently in Cornea(1). The SPEED questionnaire was designed for use by eye care practices to quickly screen patients’ dry eye symptoms, and can be used to help identify patients who may benefit from the treatment for evaporative dry eye.
The SPEED questionnaire assesses frequency and severity of patients’ dry eye symptoms. It examines the occurrence of symptoms on the current day, past 72 hours and past three months. With only four simple questions, the SPEED questionnaire can be easily administered in a physicians practice in approximately two minutes. The SPEED score is then easily tallied to quickly obtain relevant dry eye patient symptom information.
“The purpose of the study conducted on the SPEED questionnaire was to characterize its psychometric properties and to compare its performance to four existing dry eye questionnaires that are commonly used to assess dry eye symptoms, the Ocular Surface Disease Index (OSDI), the Dry Eye Questionnaire (DEQ), the McMonnies Dry Eye Questionnaire (MQ) and the Subjective Evaluation of Symptom of Dryness (SESoD). The SPEED questionnaire proved to be a simple and effective way to evaluate patients’ dry eye symptoms,” said Professor Lyndon Jones from the School of Optometry and Vision Science at the University of Waterloo. “The results showed that the SPEED questionnaire is repeatable, valid, and performs comparably with other existing questionnaires.”
“Validation of the SPEED questionnaire confirms what we already knew about its usefulness in identifying patients that may benefit from evaporative dry eye treatment,” said Donald R. Korb, OD, chief technology officer and co-founder of TearScience. “However, now the eye care industry can adopt the SPEED with the same confidence level they have in using OSDI.”
TearScience® focuses on the most common form of dry eye, evaporative dry eye. Eight-six percent of the more than 275 million worldwide sufferers have this form of dry eye. TearScience® estimates the market potential in North America alone to be more than $10 billion. Despite the high spend to manage dry eye, patients continue to be frustrated with traditional therapies and are seeking alternatives that will provide better symptom relief. The TearScience® Dry Eye solution provides a simple three-step approach to assessing the patient level of discomfort, then identifies and treats the most prevalent disease in eye care.
1) Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness Questionnaire. Ngo W, Situ P, Keir N, Korb D, Blackie C, & Simpson T. Cornea. 2013 Sep; 32(9):1204-10.